Our services to fit your needs

Because phenotypic screening is a global approach on cells and is performed by High Content Screening (HCS)


This technology allows phenotypic screening to discover new compounds and new targets for complex diseases, such as neurodegenerative diseases and cancer



HCS main assets for active cosmetic ingredients

Gut microbiota


Confirming the efficacy of nutraceuticals and functional food is a key for the development of new compounds. High content in vitro assays play a role in researching and developing new actives ingredients dedicated to human and animals food.



Phenotypic screening by High Content Screening allows analysing toxic events, as genotoxicity, hepatotoxicity, neurotoxicity or cardiotoxicity at the early stage of research.

Add the extracellular matrix in your 3D cellular assays

BIOMIMESYS® 3D technology is a natural HA-based scaffold to better mimic the tissue microenvironment and provide more predictive tools for drug development. The BIOMIMESYS® products are formed by crosslinking reaction of hydrosoluble modified hyaluronic acid and others matrix components with ADH (adipic acid dihydrazide), to mimic the extracellular matrix (ECM). Depending on the organ, ECM components vary and are present in different proportions, allowing a more or less dense and compact cellular environment. BIOMIMESYS® 3D technology allows us to reproduce the cell microenvironment of each organ.

Click here to get more information!


Last news from HCS Pharma and biotechnologies!

Projects and Distinctions

We are involved in amazing projects to improve medical and biological science and, sometime, we are rewarded for!
Jeune Entreprise Innovante

Jeune Entreprise Innovante

or "Young Innovative Company" in plain english

The status of Young Innovative Company (JEI) recognize young companies very active in R&D. this distinction is given by the french ministry of research.

CHOlesterol Personalized INnovation (CHOPIN)

CHOPIN Project

CHolesterol Personalized INnovation

Led by Pr Bertrand Cariou, director of l’institut du thorax*, the project aims at improving the management of hypercholesterolemia by identifying new markers in cardiovascular risk and new targets of LDL-cholesterol metabolism, which plays a central role in the development and progression of cardiovascular diseases.



Universal Liver in a chip

This project aims at developing a universal “plug and play” platform, flexible and modular, mimicking the major events occurring in the liver sinusoid: barrier/sieving effect resulting from the specific fenestration of liver sinusoidal endothelial cells, biotransformation and metabolism in the hepatocytes themselves.

Get in Touch

How can we help you?

Find us at the office

HCS Pharma – Siège de Lille
Biocentre Fleming Bat A
250 rue Salvador Allende
59120 LOOS
See on map

Give us a ring

+33 769 999 137
Only for customers please, if you have another interest use the form contact.

Contact Us